These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 25669949)

  • 21. Pharmacogenetics and antipsychotics: therapeutic efficacy and side effects prediction.
    Zhang JP; Malhotra AK
    Expert Opin Drug Metab Toxicol; 2011 Jan; 7(1):9-37. PubMed ID: 21162693
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Genetic variation and the risk of haloperidol-related parkinsonism in elderly patients: a candidate gene approach.
    Knol W; van Marum RJ; Jansen PA; Strengman E; Al Hadithy AF; Wilffert B; Schobben AF; Ophoff RA; Egberts TC
    J Clin Psychopharmacol; 2013 Jun; 33(3):405-10. PubMed ID: 23609402
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Antipsychotic-induced extrapyramidal side effects: A systematic review and meta-analysis of observational studies.
    Ali T; Sisay M; Tariku M; Mekuria AN; Desalew A
    PLoS One; 2021; 16(9):e0257129. PubMed ID: 34506552
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Focus on lower risk of tardive dyskinesia with atypical antipsychotics.
    Nasrallah HA
    Ann Clin Psychiatry; 2006; 18(1):57-62. PubMed ID: 16517454
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Drug therapies for tardive dyskinesia: Part 1.
    Howland RH
    J Psychosoc Nurs Ment Health Serv; 2011 Jun; 49(6):13-6. PubMed ID: 21598866
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pharmacogenetics of second-generation antipsychotics.
    Brennan MD
    Pharmacogenomics; 2014 Apr; 15(6):869-84. PubMed ID: 24897292
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Genomewide association study of movement-related adverse antipsychotic effects.
    Aberg K; Adkins DE; Bukszár J; Webb BT; Caroff SN; Miller DD; Sebat J; Stroup S; Fanous AH; Vladimirov VI; McClay JL; Lieberman JA; Sullivan PF; van den Oord EJ
    Biol Psychiatry; 2010 Feb; 67(3):279-82. PubMed ID: 19875103
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Lack of association between serotonin-2A receptor gene (HTR2A) polymorphisms and tardive dyskinesia in schizophrenia.
    Basile VS; Ozdemir V; Masellis M; Meltzer HY; Lieberman JA; Potkin SG; Macciardi FM; Petronis A; Kennedy JL
    Mol Psychiatry; 2001 Mar; 6(2):230-4. PubMed ID: 11317228
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Treatment of tardive dyskinesia.
    Widroe HJ; Heisler S
    Dis Nerv Syst; 1976 Mar; 37(3):162-4. PubMed ID: 3393
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Loss of dopamine neuron terminals in antipsychotic-treated schizophrenia; relation to tardive dyskinesia.
    Seeman P; Tinazzi M
    Prog Neuropsychopharmacol Biol Psychiatry; 2013 Jul; 44():178-83. PubMed ID: 23454261
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pharmacogenetics of clinical response to risperidone.
    Llerena A; Berecz R; Peñas-Lledó E; Süveges A; Fariñas H
    Pharmacogenomics; 2013 Jan; 14(2):177-94. PubMed ID: 23327578
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Tardive dyskinesia induced by classical antipsychotic drugs: a Tunisian sample of schizophrenics].
    Sejil I; Oumaya A; Bouguerra C; Mehdi F; Bellaaj R; Gallali S
    Encephale; 2013 May; 39 Suppl 1():S36-41. PubMed ID: 23219594
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pharmacogenetics and pharmacogenomics of schizophrenia: a review of last decade of research.
    Arranz MJ; de Leon J
    Mol Psychiatry; 2007 Aug; 12(8):707-47. PubMed ID: 17549063
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Epidemiology of tardive dyskinesia before and during the era of modern antipsychotic drugs.
    Tarsy D; Lungu C; Baldessarini RJ
    Handb Clin Neurol; 2011; 100():601-16. PubMed ID: 21496610
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The genetics of drug-related movement disorders, an umbrella review of meta-analyses.
    van der Burg NC; Al Hadithy AFY; van Harten PN; van Os J; Bakker PR
    Mol Psychiatry; 2020 Oct; 25(10):2237-2250. PubMed ID: 32020047
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pharmacogenetics of antipsychotic treatment in schizophrenia.
    Pouget JG; Müller DJ
    Methods Mol Biol; 2014; 1175():557-87. PubMed ID: 25150876
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The pharmacogenetics of antipsychotic-induced adverse events.
    Müller DJ; Chowdhury NI; Zai CC
    Curr Opin Psychiatry; 2013 Mar; 26(2):144-50. PubMed ID: 23370274
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pharmacogenetics-Guided Advances in Antipsychotic Treatment.
    Islam F; Men X; Yoshida K; Zai CC; Müller DJ
    Clin Pharmacol Ther; 2021 Sep; 110(3):582-588. PubMed ID: 34129738
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Animal models of tardive dyskinesia.
    Kulkarni SK; Dhir A
    Int Rev Neurobiol; 2011; 98():265-87. PubMed ID: 21907091
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Drug-induced movement disorders.
    Mehta SH; Morgan JC; Sethi KD
    Neurol Clin; 2015 Feb; 33(1):153-74. PubMed ID: 25432728
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.